FORTEO® (teriparatide [rDNA origin] injection): Bone Mineral Density Response

Detailed Information

Effects of Teriparatide on BMD in Postmenopausal Women With Osteoporosis

Results from a LOCF analysis showed that teriparatide significantly increased baseline to endpoint BMD at the LS, FN, and TH in postmenopausal women with osteoporosis.¹

Table 1. Mean Percentage Change in BMD From Baseline to Endpoint^a in Postmenopausal Women With Osteoporosis Treated With Teriparatide for a Median of 19 Months ¹

	Teriparatide n=541	Placebo n=544
LS BMD	9.7%b	1.1%
FN BMD	2.8%c	-0.7%
TH BMD	2.6%c	-1.0%

Abbreviations: BMD = bone mineral density; FN = femoral neck; LS = lumbar spine; TH = total hip.

^a Intent-to-treat analysis, last observation carried forward.

^b p<.001 compared with placebo.

^c p<.05 compared with placebo.

In a subset of women for whom data were available at every time point (3, 6, 12, and 18 months; n=129), teriparatide significantly increased LS BMD by 3.9% at 3 months of treatment and 11.8% at 18 months.²

Effects of Teriparatide on BMD in Men With Primary or Hypogonadal Osteoporosis

Using a LOCF analysis, results showed that teriparatide treatment, for a median of 10 months, significantly increased baseline LS BMD by 5.9% compared to placebo (p<.001). Significant increases in LS BMD were seen at 3 months.¹

Teriparatide treatment significantly increased FN BMD by 1.5% from baseline compared to the placebo group (p<.05).¹

There was no significant difference observed in the change from baseline to endpoint TH BMD.¹

Effects of Teriparatide on BMD in Men and Women With Glucocorticoid-Induced Osteoporosis

Results from a LOCF analysis showed that teriparatide significantly increased baseline to endpoint BMD at the LS, FN, and TH by 7.2%, 3.7%, and 3.6%, respectively, at the 18-month endpoint (p<.001 at all sites).¹

Enclosed Prescribing Information

FORTEO^® (teriparatide [rDNA origin] injection), Lilly

Reference

1. Forteo [package insert]. Indianapolis IN: Eli Lilly and Company; 2019.

2. Data on file, Eli Lilly and Company and/or one of its subsidiaries.

Glossary

BMD = bone mineral density

FN = femoral neck

LS = lumbar spine

LOCF = last observation carried forward

TH = total hip